Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Business Wire•06/11/2026•16:01 ET
0
Key Highlights
- ➤Viridian will present VRDN-008 phase 1 data on November 9, 2026
- ➤Company will outline development plans for its FcRn portfolio
- ➤Viridian is advancing elegrobart, a late-stage investigational subcutaneous TED therapy
- ➤Lumvoa is FDA-approved for treating thyroid eye disease
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET.
Get started
Create a free account to read the full story.